Shenzhen Kangtai Biological Products Co Ltd (300601) - Total Liabilities
Based on the latest financial reports, Shenzhen Kangtai Biological Products Co Ltd (300601) has total liabilities worth CN¥4.32 Billion CNY (≈ $632.34 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shenzhen Kangtai Biological Products Co Ltd - Total Liabilities Trend (2012–2025)
This chart illustrates how Shenzhen Kangtai Biological Products Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Shenzhen Kangtai Biological Products Co short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Shenzhen Kangtai Biological Products Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shenzhen Kangtai Biological Products Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
American Superconductor Corporation
NASDAQ:AMSC
|
USA | $184.03 Million |
|
Mesoblast Ltd
AU:MSB
|
Australia | AU$207.62 Million |
|
Dgb Financial
KO:139130
|
Korea | ₩96.18 Trillion |
|
FAIRFAX INDIA HLDGS
F:F5X
|
Germany | €772.00 Million |
|
Vietnam National Petroleum Group
VN:PLX
|
Vietnam | ₫77.19 Trillion |
|
Surgery Partners Inc
NASDAQ:SGRY
|
USA | $4.39 Billion |
|
Horace Mann Educators Corporation
NYSE:HMN
|
USA | $13.50 Billion |
|
EMBOTELL. ANDINA ADR A/6
F:AKOA
|
Germany | €2.13 Trillion |
Liability Composition Analysis (2012–2025)
This chart breaks down Shenzhen Kangtai Biological Products Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Shenzhen Kangtai Biological Products Co .
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenzhen Kangtai Biological Products Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenzhen Kangtai Biological Products Co Ltd (2012–2025)
The table below shows the annual total liabilities of Shenzhen Kangtai Biological Products Co Ltd from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥4.46 Billion ≈ $653.20 Million |
-8.95% |
| 2024-12-31 | CN¥4.90 Billion ≈ $717.42 Million |
-11.56% |
| 2023-12-31 | CN¥5.54 Billion ≈ $811.21 Million |
+15.47% |
| 2022-12-31 | CN¥4.80 Billion ≈ $702.54 Million |
-3.64% |
| 2021-12-31 | CN¥4.98 Billion ≈ $729.06 Million |
+134.89% |
| 2020-12-31 | CN¥2.12 Billion ≈ $310.38 Million |
+77.03% |
| 2019-12-31 | CN¥1.20 Billion ≈ $175.33 Million |
-20.32% |
| 2018-12-31 | CN¥1.50 Billion ≈ $220.03 Million |
+31.93% |
| 2017-12-31 | CN¥1.14 Billion ≈ $166.77 Million |
+31.62% |
| 2016-12-31 | CN¥865.90 Million ≈ $126.71 Million |
+26.09% |
| 2015-12-31 | CN¥686.71 Million ≈ $100.49 Million |
-9.44% |
| 2014-12-31 | CN¥758.25 Million ≈ $110.96 Million |
+3.20% |
| 2013-12-31 | CN¥734.74 Million ≈ $107.52 Million |
+4.14% |
| 2012-12-31 | CN¥705.50 Million ≈ $103.24 Million |
-- |
About Shenzhen Kangtai Biological Products Co Ltd
Shenzhen Kangtai Biological Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of human vaccines in China and internationally. The company offers 13-valent pneumococcal polysaccharide conjugate vaccines (TT/DT); varicella vaccines (freeze-dried); hepatitis B vaccines; 23-valent pneumococcal polysaccharide vaccines; diphtheria tetanus ace… Read more